원발성 간암과 췌장암에 있어서의 αFP , TATI 및 CA 19 - 9 의 임상적 의의

The aim of this study was to evaluate the usefulness of measuring more than two tumor markers including TATI in the diagnosis of pancreatic cancer and hepatoma. Pancreatic cancer patients (10); The range of serum CA 19-9 concentration was 55.01-231 U/ml. All of 10 (100%) had increased value (>33U/ml). Nine of 10 patients (90%) had CA 19-9 values above the cancer diagnostic cut off level (>100U/ml). Serum TATI concentration were raised (range 26.47-450 pg/,L ) in 80% (8/10) of the patients. Serum TATI concentration was above cut off level (40pg/I ) in 5 patients (50%). One patient, who had non diagnostic CA19-9 level (42.9 U/ml), had 413.47 pg/Lof serum TATI concentration. Thus when the two tumor markers (CA19-9, TATI) were used together, all of 10 pancreatic cancer patients (100%) had diagnostic cut off level. Primary hepatoma patients (22); Serum aFP value were raised in 86.36% (19/22) of the patients (range 14.26-2014 pg/ml). Six patients had value of non diagnostic range (14.26-237 pg/ml), so that 59. 09% (13/22) of the patients had a diagnostic aFP value (>400pg/ml). Serum TATI values were raised in 77.2% (17/22) of the patients. 59% (13/22) of the patients had serum TATI value above the cut off level. Of the 6 patients who had non diagnostic a FP level, three patients had serum TATI value above cut off level. When serum n FP and TATI were measured together, 81.8% (18/22) of the patients had at least one of the value above cut off level. So if the two tumor markers were used together (CA19-9 and TATI in pancreatic cancer, aFP and TATI in primary hepatoma) it might be helpful in some patients in the diagnosis of malignancy. But accounting economical and other factors, we think it needs further evaluation.